Yang Dou, Ke Xu, Yong-Qiang Deng, Zijing Jia, Jun Lan, Xiaoyu Xu, Guorui Zhang, Tianshu Cao, Pan Liu, Xiangxi Wang, Xinquan Wang, Lingjie Xu, Pan Du, Cheng-Feng Qin, Hong Liu, Yafeng Li, Guizhen Wu, Kang Wang, Bai Lu
{"title":"利用高通量单b细胞克隆方法制备抗SARS-CoV-2的中和抗体。","authors":"Yang Dou, Ke Xu, Yong-Qiang Deng, Zijing Jia, Jun Lan, Xiaoyu Xu, Guorui Zhang, Tianshu Cao, Pan Liu, Xiangxi Wang, Xinquan Wang, Lingjie Xu, Pan Du, Cheng-Feng Qin, Hong Liu, Yafeng Li, Guizhen Wu, Kang Wang, Bai Lu","doi":"10.1093/abt/tbad002","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Rapid and efficient strategies are needed to discover neutralizing antibodies (nAbs) from B cells derived from virus-infected patients.</p><p><strong>Methods: </strong>Here, we report a high-throughput single-B-cell cloning method for high-throughput isolation of nAbs targeting diverse epitopes on the SARS-CoV-2-RBD (receptor binding domain) from convalescent COVID-19 patients. This method is simple, fast and highly efficient in generating SARS-CoV-2-neutralizing antibodies from COVID-19 patients' B cells.</p><p><strong>Results: </strong>Using this method, we have developed multiple nAbs against distinct SARS-CoV-2-RBD epitopes. CryoEM and crystallography revealed precisely how they bind RBD. In live virus assay, these nAbs are effective in blocking viral entry to the host cells.</p><p><strong>Conclusion: </strong>This simple and efficient method may be useful in developing human therapeutic antibodies for other diseases and next pandemic.</p>","PeriodicalId":36655,"journal":{"name":"Antibody Therapeutics","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/e3/be/tbad002.PMC10108556.pdf","citationCount":"0","resultStr":"{\"title\":\"Development of neutralizing antibodies against SARS-CoV-2, using a high-throughput single-B-cell cloning method.\",\"authors\":\"Yang Dou, Ke Xu, Yong-Qiang Deng, Zijing Jia, Jun Lan, Xiaoyu Xu, Guorui Zhang, Tianshu Cao, Pan Liu, Xiangxi Wang, Xinquan Wang, Lingjie Xu, Pan Du, Cheng-Feng Qin, Hong Liu, Yafeng Li, Guizhen Wu, Kang Wang, Bai Lu\",\"doi\":\"10.1093/abt/tbad002\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Rapid and efficient strategies are needed to discover neutralizing antibodies (nAbs) from B cells derived from virus-infected patients.</p><p><strong>Methods: </strong>Here, we report a high-throughput single-B-cell cloning method for high-throughput isolation of nAbs targeting diverse epitopes on the SARS-CoV-2-RBD (receptor binding domain) from convalescent COVID-19 patients. This method is simple, fast and highly efficient in generating SARS-CoV-2-neutralizing antibodies from COVID-19 patients' B cells.</p><p><strong>Results: </strong>Using this method, we have developed multiple nAbs against distinct SARS-CoV-2-RBD epitopes. CryoEM and crystallography revealed precisely how they bind RBD. In live virus assay, these nAbs are effective in blocking viral entry to the host cells.</p><p><strong>Conclusion: </strong>This simple and efficient method may be useful in developing human therapeutic antibodies for other diseases and next pandemic.</p>\",\"PeriodicalId\":36655,\"journal\":{\"name\":\"Antibody Therapeutics\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/e3/be/tbad002.PMC10108556.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Antibody Therapeutics\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1093/abt/tbad002\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Antibody Therapeutics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/abt/tbad002","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
Development of neutralizing antibodies against SARS-CoV-2, using a high-throughput single-B-cell cloning method.
Background: Rapid and efficient strategies are needed to discover neutralizing antibodies (nAbs) from B cells derived from virus-infected patients.
Methods: Here, we report a high-throughput single-B-cell cloning method for high-throughput isolation of nAbs targeting diverse epitopes on the SARS-CoV-2-RBD (receptor binding domain) from convalescent COVID-19 patients. This method is simple, fast and highly efficient in generating SARS-CoV-2-neutralizing antibodies from COVID-19 patients' B cells.
Results: Using this method, we have developed multiple nAbs against distinct SARS-CoV-2-RBD epitopes. CryoEM and crystallography revealed precisely how they bind RBD. In live virus assay, these nAbs are effective in blocking viral entry to the host cells.
Conclusion: This simple and efficient method may be useful in developing human therapeutic antibodies for other diseases and next pandemic.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
